GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Gross Profit

Hansa Biopharma AB (OSTO:HNSA) Gross Profit : kr94.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Gross Profit?

Hansa Biopharma AB's gross profit for the three months ended in Mar. 2024 was kr37.8 Mil. Hansa Biopharma AB's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was kr94.2 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Hansa Biopharma AB's gross profit for the three months ended in Mar. 2024 was kr37.8 Mil. Hansa Biopharma AB's Revenue for the three months ended in Mar. 2024 was kr56.0 Mil. Therefore, Hansa Biopharma AB's Gross Margin % for the quarter that ended in Mar. 2024 was 67.56%.

Hansa Biopharma AB had a gross margin of 67.56% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Hansa Biopharma AB was 93.58%. The lowest was 52.91%. And the median was 75.10%.

Warning Sign:

Hansa Biopharma AB gross margin has been in long-term decline. The average rate of decline per year is -5.5%.


Hansa Biopharma AB Gross Profit Historical Data

The historical data trend for Hansa Biopharma AB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Gross Profit Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.50 5.10 18.45 116.05 70.95

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.55 17.94 6.18 32.29 37.82

Competitive Comparison of Hansa Biopharma AB's Gross Profit

For the Biotechnology subindustry, Hansa Biopharma AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Gross Profit distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Gross Profit falls into.



Hansa Biopharma AB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Hansa Biopharma AB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=134.094 - 63.143
=71.0

Hansa Biopharma AB's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=55.981 - 18.158
=37.8

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr94.2 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Hansa Biopharma AB's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=37.8 / 55.981
=67.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Hansa Biopharma AB  (OSTO:HNSA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hansa Biopharma AB had a gross margin of 67.56% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Hansa Biopharma AB Gross Profit Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines